Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401128 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00401128: Completed Phase 2 study of Kidney Cancer, sponsored by The Cleveland Clinic.
NCT00401128 is a Phase 2 study of Kidney Cancer that has completed, run by The Cleveland Clinic. The registered enrollment target is 9 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00401128, a Phase 2 study of Kidney Cancer, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
- DRUG gemcitabine hydrochloride
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00401128 record still lists
NCT00401128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which irinotecan hydrochloride is the first listed.
NCT00401128 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00401128 about?
NCT00401128 is a clinical study titled "Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II ...
What is the current status of trial NCT00401128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-05. Estimated completion is 2007-02.
What conditions does trial NCT00401128 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00401128?
The interventions under investigation include: irinotecan hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00401128?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00401128 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00401128's enrollment target sits among peer trials
9 59th of 60 higher than 1 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia